JAZZ News and Press, Jazz Pharmaceuticals plc From 03/30/22

The world is abuzz once again with interest in cannabis stocks thanks to the continuing legislative momentum of critical bills now making their way through Congress. The Marijuana Opportunity, Reinvestment and Expungement Act (the “MORE Act”) is a bill sponsored by House Judicia...

Jazz Pharmaceuticals to Participate in Upcoming April Investor Conferences PR Newswire DUBLIN , March 29, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor con...

The shares of Axsome Therapeutics (NASDAQ:AXSM +12.9%) have reached the highest level since November after Truist Securities raised the price target of the clinical-stage pharma company on Tuesday, citing its deal to acquire Sunosi (solriamfetol) from Jazz Pharmaceuticals (JAZZ +0.4%). S...

Apple (NASDAQ:AAPL) took the spotlight in Monday's pre-market trading. The company won a Best Picture Oscar, but shares lost ground amid reports that it is cutting back production of certain products. Tesla (TSLA) represented another big name garnering attention before the bell. Shares of Elo...

Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics PR Newswire Jazz to receive $53 million upfront cash payment, and royalty rights Transaction designed to ensure uninterrupted patient access to Sunosi ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) and its subsidiary, GW Pharmaceuticals (OTCPK:GWPRF) announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne. The construction begins on a new state-of-the-art manufact...

Jazz Pharmaceuticals (NASDAQ:JAZZ) said the first patient was enrolled in a phase 2 trial evaluating Zepzelca (lurbinectedin) as a monotherapy in three groups: patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination deficient (...

Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors PR Newswire Open-label basket trial will assess the safety and eff...

We are initiating AVDL at a speculative buy rating, with a target price of USD 14. We like AVDL's lead candidate FT218, and we believe the upcoming PDUFA on March 31st to be the critical catalyst for the company. We believe AVDL will be able to generate USD ~300M peak sales. ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with this event. For further details see: Jazz Pharmaceuticals (JAZZ) Presents at the Needham Virtual Neuroscience Forum - Slideshow